Insight

Piotr Wysocki: How can we optimize the endocrine treatment of advanced HR+/HER2- breast cancer?

Photo taken from Piotr Wysocki/LinkedIn

Mar 23, 2024, 04:35

Piotr Wysocki: How can we optimize the endocrine treatment of advanced HR+/HER2- breast cancer?

Piotr Wysocki, Professor of Medicine, Head of Department of Oncology at Jagiellonian University Hospital, recently shared on LinkedIn:

“I want to share with you my personal view on the optimal utilisation of currently available treatments for advanced HR+/HER2- breast cancer. The review published online in JCO Oncology Practice summarizes the available data on the efficacy and safety of various therapeutic strategies in relationship to current reimbursement limitations in Poland and many other EU countries (lack of reimbursement of everolimus and unavailability of capivasertib). You can download the whole paper here.”

Source: Piotr Wysocki/LinkedIn

Breast Cancer cancer Capivasertib endocrine treatment everolimus HR+/HER2- breast cancer JCO Oncology Practice OncoDaily Oncology Piotr Wysocki Poland review treatments for cancer

Oncologist Near Me - Vivek Subbiah: Pionner of Precision Oncology

Monica Bertagnolli is ending her tenure as NIH director

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success